Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Gastrointestinal Stromal Tumors × ripretinib × Clear all

Phase

Status

Completed 5 Recruiting 2 Active not recruiting 2 Withdrawn 1 Unknown 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

trametinib 1 ripretinib 1 pazopanib 1 nilotinib 1 binimetinib 1 Imatinib Mesylate 1 High-Energy Shock Waves 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05080621 2022-01-05

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Deciphera Pharmaceuticals, LLC

Phase 1/2 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡